Larson Financial Group’s Cytek Biosciences CTKB Stock Holding History

Larson Financial Group’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93K	Sell	435 -36	-8%	-$154	﹤0.01%	3133
2026 Q1	$2.06K	Buy	471 +417	+772%	+$1.97K	﹤0.01%	2955
2025 Q4	$273	Buy	+54	New	+$251	﹤0.01%	3230
2025 Q3	–	Sell	-20	Closed	-$68	–	3492
2025 Q2	$68	Sell	20 -4	-17%	-$13	﹤0.01%	3207
2025 Q1	$96	Hold	24	–	–	﹤0.01%	2918
2024 Q4	$156	Hold	24	–	–	﹤0.01%	2508
2024 Q3	$133	Hold	24	–	–	﹤0.01%	2477
2024 Q2	$134	Buy	+24	New	+$144	﹤0.01%	2185

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Larson Financial Group's CTKB Position: Q2 2026 in Review

Larson Financial Group reduced its Cytek Biosciences (CTKB) stake by 7.6% in Q2 2026, selling an estimated $154 and leaving 435 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #3133.

Larson Financial Group first reported a position in CTKB in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.06K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Larson Financial Group held 435 shares of Cytek Biosciences worth $1.93K as of Q2 2026.
Larson Financial Group sold 36 Cytek Biosciences shares in Q2 2026, an estimated $154.
Cytek Biosciences made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3133 holding.
Larson Financial Group first reported a position in Cytek Biosciences in Q2 2024 and has held it in 8 quarters since.
Larson Financial Group's Cytek Biosciences position peaked at $2.06K in Q1 2026.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.